Quick Answer
Translational Development Acquisition Corp. reported Operating Income of -$944.5 thousand for fiscal year 2025.
Translational Development Acquisition Corp. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$944.5K | -381.0% |
| 2024 | -$196.4K | +59.6% |
| 2023 | -$485.6K | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$213.7K | -248.6% | +3.4% |
| June 30, 2025 | -$221.1K | -13023.3% | +36.3% |
| March 31, 2025 | -$347.4K | — | -466.9% |
| September 30, 2024 | -$61.3K | — | -3537.0% |
| June 30, 2024 | -$1.7K | — | — |
| March 31, 2024 | $0.00 | — | — |
- Translational Development Acquisition Corp. showed a decrease of -381.0% in Operating Income compared to the prior fiscal year.
- Over the 2023–2025 period, Translational Development Acquisition Corp.’s operating income has declined by 94.5% (from -$485.6 thousand to -$944.5 thousand).
- The most recent figure is from Translational Development Acquisition Corp.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 30, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: